Approval by the European Commission makes Jardiance an option for approximately 47 million people in the EU who are living with CKD, according to a joint statement from Boehringer and Lilly.

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance fails to hit the mark when used in post-myocardial infarction patients.